Last updated on January 2019

Combination Treatment for Augmenting Language in Children With ASD

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pervasive developmental disorder
  • Age: Between 5 - 11 Years
  • Gender: Male or Female

Inclusion criteria:

  • boys and girls ages 5-11 years;
  • criteria for autistic disorder or PDD-NOS as defined by DSM-IV-TR and confirmed by clinical examination and ADI-R, ADOS;
  • low language usage as defined by <30 functional words obtained from a natural language sample, parent report, and standardized tests;
  • present placement in a comprehensive educational/intervention setting.

Exclusion criteria:

  • any medical condition that would interfere with intervention outcomes during a 12 week study period (eg., active seizures within 3 months);
  • genetic disorders such as Fragile X, Down syndrome, or tuberous sclerosis;
  • sensory impairments such as deafness or blindness;
  • existing or anticipated need for concomitant psychotropic medication (specifically stimulants, atomoxetine) during study participation( allowed medication include: antidepressants, anticonvulsants, guanfacine, clonidine, supplements, melatonin, diphenhydramine);
  • severe aggression or self-injurious behavior;
  • DQ <18 months as assessed by the Leiter-Revised or Mullen.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.